Cong Xu, Chen Zhang, Kumar Ganesan, Qiu Chen, Hailin Tang, Fei Gao, Qingqing Liu, Jianming Wu, Yue Sui, Peng Li, Jinming Zhang and Jianping Chen* Pages 1 - 19 ( 19 )
Introduction: Triple-negative breast cancer (TNBC), an aggressive type of breast cancer, remains difficult to treat. Isoliquiritigenin (ISL) is a bioactive compound that is insoluble in water and exhibits significant anti-TNBC activity.
Method: We previously prepared oral aqueous ISL@ZLH NPs; however, they were less stable in a freezing environment. Hence, the present study aimed to improve the stability of ISL@ZLH NPs using cryoprotectants that can withstand long storage times and are effective in TNBC treatment by creating an efficient oral drug delivery system. Freeze-dried ISL@ZLH NP powder was prepared by solvent evaporation, followed by the addition of trehalose and sucrose. The freeze-dried ISL@ZLH NP pow was optimized and characterized. The anti-TNBC efficacy and pharmacokinetics of the ISL@ZLH NP-pow were examined in plasma and organs, compared with those of aqueous ISL@ZLH NPs.
Result: The ideal particle size of the ISL@ZLH NP pow was 118 nm, which was not filtered out by the glomerulus and allowed the drug to be delivered to the lesions more effectively. Cellular uptake and biodistribution of the ISL@ZLH NP-pow in vivo and in vitro showed prolonged storage in the organs. In addition, cryopreserved ISL@ZLH NP-treated tumors showed significant anti-proliferative and anti-migratory effects through the downregulation of the PI3K-Akt-mToR and MMP2/9 signaling pathways.
Conclusion: These results suggest that oral ingestion of cryopreserved ISL@ZLH NP has the potential for longterm storage and can be employed as a clinical therapeutic approach to treat TNBC.
ISL@ZLH NP,cryopreservation,TNBC,PI3K-Akt-mToR,MMP2/9 signaling